| Acute lymphocytic leukemia
Asparlas vs Leukine
Side-by-side clinical, coverage, and cost comparison for acute lymphocytic leukemia.Deep comparison between: Asparlas vs Leukine with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLeukine has a higher rate of injection site reactions vs Asparlas based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Leukine but not Asparlas, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Asparlas
Leukine
At A Glance
IV infusion
Every 21 days
Pegylated L-asparaginase
IV infusion or SC injection
Once daily
GM-CSF
Indications
- Acute lymphocytic leukemia
- Leukemia, Myelocytic, Acute
- Lymphoma, Non-Hodgkin
- Acute lymphocytic leukemia
- Hodgkin Disease
- Hematopoietic subsyndrome of acute radiation syndrome
Dosing
Acute lymphocytic leukemia 2,500 units/m2 intravenously no more frequently than every 21 days.
Leukemia, Myelocytic, Acute 250 mcg/m2/day IV over a 4-hour period starting day 11 or four days after induction chemotherapy completion; continue until ANC >1500 cells/mm3 for 3 consecutive days or up to 42 days.
Lymphoma, Non-Hodgkin, Acute lymphocytic leukemia, Hodgkin Disease 250 mcg/m2/day IV over 24 hours or SC once daily beginning immediately following progenitor cell infusion; continue until ANC >1500 cells/mm3 for three consecutive days.
Autologous or allogeneic bone marrow transplantation 250 mcg/m2/day IV over a 2-hour period beginning 2-4 hours after bone marrow infusion; continue until ANC >1500 cells/mm3 for three consecutive days.
Delayed neutrophil recovery or graft failure 250 mcg/m2/day for 14 days as a 2-hour IV infusion; may repeat after 7 days off therapy if neutrophil recovery has not occurred, up to three courses.
Hematopoietic subsyndrome of acute radiation syndrome SC injection once daily: 7 mcg/kg for adults and pediatric patients >40 kg, 10 mcg/kg for pediatric patients 15-40 kg, 12 mcg/kg for pediatric patients <15 kg; continue until ANC >1000/mm3 for three consecutive CBCs.
Contraindications
- History of serious hypersensitivity reactions, including anaphylaxis, to pegylated L-asparaginase therapy
- History of serious pancreatitis during previous L-asparaginase therapy
- History of serious thrombosis during previous L-asparaginase therapy
- History of serious hemorrhagic events during previous L-asparaginase therapy
- Severe hepatic impairment
- History of serious allergic reactions, including anaphylaxis, to sargramostim, yeast-derived products, or any component of the product
Adverse Reactions
Most common Elevated transaminase, bilirubin increased, pancreatitis, abnormal clotting studies, diarrhea, hypersensitivity, embolic and thrombotic events, sepsis, dyspnea, hemorrhages, fungal infection, pneumonia, arrhythmia, cardiac failure
Serious Hypersensitivity, pancreatitis, thrombosis, hemorrhage, hepatotoxicity including veno-occlusive disease
Postmarketing Veno-occlusive disease (hepatic)
Most common (>=10%) Fever, nausea, diarrhea, vomiting, rash, alopecia, stomatitis, asthenia, malaise, anorexia, edema, headache, chills, peripheral edema, dyspnea
Serious Hypersensitivity and anaphylaxis, infusion-related reactions, severe myelosuppression, effusions, capillary leak syndrome, supraventricular arrhythmias, leukocytosis
Postmarketing Infusion-related reactions, serious allergic reactions including anaphylaxis, effusions, capillary leak syndrome, supraventricular arrhythmias, leukocytosis including eosinophilia, thromboembolic events, injection site reactions
Pharmacology
Pegylated L-asparaginase enzyme that depletes plasma asparagine by catalyzing its conversion to aspartic acid and ammonia; leukemic cells with low asparagine synthetase expression depend on exogenous asparagine for survival and are killed by its depletion.
Sargramostim (GM-CSF) is a colony-stimulating factor that supports survival, clonal expansion, and differentiation of hematopoietic progenitor cells, inducing partially committed progenitors to divide and differentiate into granulocyte-macrophage pathways including neutrophils, monocytes/macrophages, and myeloid-derived dendritic cells; it can also activate mature granulocytes and macrophages and promote proliferation of megakaryocytic and erythroid progenitors.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Asparlas
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Leukine
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (6/12) · Qty limit (0/12)
UnitedHealthcare
Asparlas
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Leukine
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Asparlas
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Leukine
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Asparlas Patient Assistance ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCancerCare: Chemotherapy Induced Neutropenia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AsparlasView full Asparlas profile
LeukineView full Leukine profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.